List of Excipients in Branded Drug MICROGESTIN 1/20

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
RPK Pharmaceuticals Inc	MICROGESTIN 1/20	norethindrone acetate and ethinyl estradiol	53002-1549	ACACIA
RPK Pharmaceuticals Inc	MICROGESTIN 1/20	norethindrone acetate and ethinyl estradiol	53002-1549	LACTOSE
RPK Pharmaceuticals Inc	MICROGESTIN 1/20	norethindrone acetate and ethinyl estradiol	53002-1549	MAGNESIUM STEARATE
RPK Pharmaceuticals Inc	MICROGESTIN 1/20	norethindrone acetate and ethinyl estradiol	53002-1549	STARCH, CORN
RPK Pharmaceuticals Inc	MICROGESTIN 1/20	norethindrone acetate and ethinyl estradiol	53002-1549	SUCROSE
RPK Pharmaceuticals Inc	MICROGESTIN 1/20	norethindrone acetate and ethinyl estradiol	53002-1549	TALC

Last updated: August 15, 2026

Microgestin 1/20 is an established combined oral contraceptive containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg. Its commercial opportunity is not conventional composition-of-matter exclusivity. The stronger opportunities are low-cost generic supply, excipient optimization, packaging and stability improvements, patient-friendly dosage forms, and line extensions such as iron-containing placebo tablets. Any reformulation must preserve dissolution, content uniformity, hormonal potency, impurity control, and FDA bioequivalence.

Microgestin 1/20 Excipient Strategy and Commercial Opportunities

What is Microgestin 1/20 and how is it formulated?

Microgestin 1/20 is a low-dose combined oral contraceptive tablet. Each active tablet contains:

Component	Amount per active tablet	Function
Norethindrone acetate	1 mg	Progestin
Ethinyl estradiol	20 mcg	Estrogen
Pharmaceutical excipients	Variable	Dilution, binding, disintegration, lubrication and tablet protection

Microgestin 1/20 is generally supplied as a 21-day regimen of active tablets. Microgestin Fe 1/20 adds seven non-hormonal tablets containing ferrous fumarate. Product-specific inactive ingredients can differ by manufacturer and presentation, so the approved labeling for the target product should control any development or substitution decision.[1]

The low dose of ethinyl estradiol creates the central formulation challenge. The active drug represents a very small fraction of total tablet mass. Excipient selection and blending therefore have a direct effect on dose uniformity, segregation, dissolution and manufacturing yield.

What excipients are associated with Microgestin 1/20?

Public labeling for norethindrone acetate and ethinyl estradiol tablets identifies conventional oral-solid-dose excipients, including lactose, starch, magnesium stearate and talc in some presentations.[1] The exact formulation may differ between branded Microgestin, authorized generic products and independently approved ANDA products.

The commercial formulation baseline is therefore a conventional immediate-release tablet:

• Lactose or another water-soluble filler to establish tablet mass.
• Starch or a comparable disintegrant and binder.
• Magnesium stearate as a lubricant.
• Talc or another glidant and anti-adherent where permitted by the formulation.
• Film-coating materials, pigments and opacifiers where the product is coated.

A generic manufacturer should not assume that matching the public inactive-ingredient list will reproduce the reference product's performance. The relevant regulatory standard is pharmaceutical equivalence and bioequivalence, not excipient identity alone.[2]

What excipient strategy is appropriate for Microgestin 1/20?

The most defensible strategy is a risk-based, low-dose tablet platform designed around uniform distribution of ethinyl estradiol.

1. Control low-dose active distribution

Ethinyl estradiol is present at only 20 mcg per active tablet. Direct blending into a large excipient volume can create segregation and sampling risk. Suitable approaches include:

• Geometric dilution with controlled blending.
• Ordered mixing using a preblend of ethinyl estradiol with a carrier.
• Wet or dry granulation where needed to improve uniformity.
• Particle-size engineering or use of a spray-dried active premix.
• Dedicated in-process controls for blend uniformity and tablet assay.

A direct-compression platform can reduce processing steps, but it requires strong flow, compressibility and segregation control. Roller compaction or wet granulation can improve blend robustness but increases process complexity, validation burden and potential degradation exposure.

2. Select excipients for dissolution rather than only manufacturability

Norethindrone acetate and ethinyl estradiol have different solubility and permeability characteristics. Excessive lubricant, especially prolonged magnesium stearate blending, can slow wetting and dissolution. A formulation program should evaluate:

• Magnesium stearate concentration and blending time.
• Starch or superdisintegrant level.
• Lactose grade and particle size.
• Tablet porosity and compression force.
• Film-coating weight gain.
• Dissolution across relevant pH conditions.

The target is a robust immediate-release profile that remains within the reference-product range. A faster dissolution profile is not automatically an advantage if it creates a material difference from the reference product or increases manufacturing variability.

3. Manage stability and packaging together

Hormonal tablets require tight control of assay, related substances and physical stability. The commercial formulation should be screened under ICH stability conditions, with attention to:

• Ethinyl estradiol degradation.
• Norethindrone acetate degradation.
• Moisture uptake.
• Tablet hardness and friability.
• Coating defects.
• Blister seal integrity.
• Light exposure.
• Interaction between the formulation and packaging.

Alu-Alu blister packaging offers strong moisture and light protection but can carry higher material and conversion costs. PVC/PVdC or other blister structures may reduce cost while requiring stronger formulation and stability support. Bottles can improve packaging efficiency but may provide less unit-dose protection and may be less convenient for a 21-day or 28-day regimen.

What formulation patents protect Microgestin 1/20?

Microgestin 1/20 is an old oral contraceptive product, and the core active ingredients are long established. The principal commercial barrier is therefore unlikely to be a current composition-of-matter patent on norethindrone acetate or ethinyl estradiol.

Potentially relevant rights can instead arise from:

• A specific tablet formulation.
• A coated dosage form.
• A low-dose content-uniformity process.
• A packaging configuration.
• An iron-containing placebo tablet.
• A modified regimen or delivery system.
• A method-of-use claim directed to a specific patient population.

No current patent should be presumed enforceable or commercially relevant without a live patent-family, prosecution and claim-status review. FDA Orange Book listings should be checked for the specific reference listed drug and NDA at the time of filing.[3]

Are there method-of-use patents for Microgestin 1/20?

The principal indication is contraception. Historical method-of-use patents may have existed for oral contraceptive regimens, hormone combinations or non-contraceptive uses, but any current relevance depends on expiration, listing and claim scope.

A generic applicant must assess:

• Orange Book-listed patents.
• Paragraph IV certification exposure.
• Label carve-out options under section viii.
• Indication language in the proposed labeling.
• Whether the reference product's marketed label includes protected uses.

For a conventional norethindrone acetate/ethinyl estradiol generic, the expected legal focus is usually product approval and commercial execution rather than a new method-of-use patent position.

When does Microgestin 1/20 lose exclusivity?

The active-ingredient and original product exclusivity periods for this product class have expired. Microgestin 1/20 competes in a generic market, and the principal commercial question is not loss of exclusivity but the number, quality and reliability of available suppliers.

FDA approval of an ANDA requires pharmaceutical equivalence and bioequivalence to the reference listed drug. A generic applicant may use an abbreviated pathway rather than repeat full clinical efficacy trials, subject to FDA requirements.[2]

Exclusivity issue	Microgestin 1/20 assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Core active-ingredient patent barrier	Expected to be expired
Generic competition	Established
Current commercial barrier	Manufacturing, supply, quality, contracting and regulatory execution

What is the Orange Book status of Microgestin 1/20?

The Orange Book identifies FDA-approved drug products and relevant patent or exclusivity information. Microgestin products and their generic equivalents must be evaluated by exact NDA, strength, dosage form and active-ingredient combination.[3]

A practical Orange Book review should confirm:

1. The current reference listed drug for the 1 mg/20 mcg strength.
2. Whether the branded product remains listed as the reference product.
3. Any active patent codes.
4. Any exclusivity codes.
5. The relationship between Microgestin 1/20 and Microgestin Fe 1/20.
6. Whether the intended generic product is a 21-tablet or 28-tablet presentation.

An applicant should not treat Microgestin 1/20 and Microgestin Fe 1/20 as interchangeable development targets. The ferrous fumarate placebo tablets create a separate formulation, labeling and packaging configuration.

Which companies are challenging Microgestin 1/20?

Generic norethindrone acetate and ethinyl estradiol tablets have been marketed by multiple manufacturers over time. Manufacturer participation can change through product discontinuations, acquisitions, contract manufacturing arrangements and supply interruptions.

For competitive analysis, the most relevant data points are:

• Active ANDA holders.
• Current product availability in FDA listings.
• National Drug Code status.
• Wholesale acquisition cost and contract pricing.
• Back-order history.
• FDA inspection and warning-letter history.
• Manufacturing-site concentration.
• Availability of both 21-tablet and 28-tablet presentations.

Because this market is mature, competition is generally driven by cost and supply reliability. A new entrant with no differentiated product may face low margins and substantial price pressure.

What commercial opportunities exist for Microgestin 1/20 excipients?

Low-cost generic supply

The simplest opportunity is a conventional tablet with a validated, low-cost excipient system. Lactose, starch and magnesium stearate are widely available and familiar to FDA reviewers and contract manufacturers. The advantage is lower development risk and broader manufacturing compatibility.

The disadvantage is limited differentiation. The product must compete on reliable supply, low defect rates, regulatory compliance and purchasing terms.

Excipient substitution

Excipient substitution can create value when it improves one or more of the following:

• Blend uniformity.
• Tablet robustness.
• Dissolution consistency.
• Reduced lubricant sensitivity.
• Lower moisture sensitivity.
• Reduced coating defects.
• Better compatibility with direct compression.
• Supply-chain resilience.

Potential candidates include co-processed fillers, spray-dried lactose, silicified microcrystalline cellulose, low-substituted hydroxypropyl cellulose and modern superdisintegrants. Each change requires compatibility, stability, dissolution and bioequivalence assessment.

A new excipient with limited prior use in oral contraceptives may increase regulatory and toxicological burden. The commercial case is strongest when the excipient solves a documented manufacturing or stability problem.

Lactose-free or reduced-lactose products

A lactose-free formulation could target patients who avoid lactose or manufacturers seeking a broader excipient profile. The opportunity is commercially limited because the amount of lactose in a tablet is usually small and lactose intolerance does not necessarily preclude pharmaceutical lactose exposure.

The value proposition improves if lactose removal also improves moisture control, tablet robustness or supply continuity.

Enhanced packaging

A higher-barrier blister can support premium positioning where stability data show a measurable benefit. Calendarized packaging can reduce dispensing errors and improve regimen clarity, particularly for 28-day products.

Packaging differentiation may be more commercially practical than a novel excipient because it can improve patient handling without changing the active formulation. It still requires package-equivalency, stability and labeling work.

Microgestin Fe 1/20 line extension

The iron-containing presentation offers a distinct development opportunity. It requires:

• Separate active and placebo tablet formulation.
• Control of iron-related color and chemical interactions.
• Packaging that clearly separates active and placebo tablets.
• Distinct labeling and medication-guide review.
• Manufacturing controls to prevent tablet mix-ups.

The iron placebo tablets do not provide contraceptive activity. Their commercial value is tied to regimen completion, product differentiation and prescriber familiarity rather than treatment of iron deficiency.

Alternative dosage forms

Chewable, orally disintegrating or soft-tablet versions could improve adherence for patients with swallowing difficulty. These products would require careful evaluation of:

• Hormone uniformity at very low dose.
• Taste masking.
• Absorption profile.
• Stability.
• Patient acceptability.
• Whether the product remains eligible for an ANDA or requires a 505(b)(2) application.

A dosage form that changes administration or pharmacokinetics may lose the regulatory and cost advantages of a conventional ANDA.

How strong is the patent estate for Microgestin 1/20?

The estate should be viewed as weak for blocking generic entry and potentially stronger only around newly created formulation or device features.

Patent category	Expected strategic value
Active ingredients	Low; legacy molecules
Conventional immediate-release tablet	Low
Specific novel excipient system	Potentially moderate if claim scope and validity are strong
Packaging	Usually narrow and easy to design around
Iron-containing placebo tablets	Possible formulation and regimen claims, but likely limited
New dosage form	Potentially higher, depending on clinical and regulatory differentiation
Method of use	Dependent on claim scope, listing and expiration

A patent strategy based solely on replacing lactose, changing the lubricant or using a different disintegrant is unlikely to create durable exclusivity unless the formulation produces an unexpected technical result and the claims are drafted broadly enough to resist design-around.

What generic entry risks exist for Microgestin 1/20?

The major risks are commercial and regulatory:

• Numerous established generic suppliers.
• Low reimbursement and formulary substitution.
• Price erosion after launch.
• Limited differentiation for a conventional tablet.
• Batch failures caused by low-dose content-uniformity problems.
• Stability failures under high-moisture conditions.
• Supply disruption from a single API or tablet site.
• Confusion between 21-tablet and 28-tablet presentations.
• Packaging errors involving active and placebo tablets.
• Labeling differences that complicate pharmacy substitution.

A new entrant should prioritize a robust manufacturing process over a marginally novel excipient system. The economic value of a one-cent reduction in tablet cost can be outweighed by a single recall, shortage or failed validation campaign.

How does Microgestin 1/20 compare with competing oral contraceptives?

Microgestin 1/20 competes with other low-dose combined oral contraceptives, including products containing norethindrone, norethindrone acetate, levonorgestrel or other progestins with ethinyl estradiol.

Product characteristic	Microgestin 1/20	Higher-estrogen combined products	Progestin-only products
Estrogen dose	20 mcg ethinyl estradiol	Often 30-35 mcg or variable	None
Main formulation challenge	Very low-dose uniformity	Standard dose uniformity	Different active and regimen requirements
Placebo presentation	21-day or Fe 28-day variants	Multiple regimen formats	Product-specific
Generic competition	High	High	Increasing
Excipient differentiation	Limited but feasible	Limited	Product-dependent
Biosimilar risk	None	None	None

The product's low estrogen content can support market positioning, but excipients do not establish clinical superiority. Commercial claims must remain consistent with the approved label and applicable advertising rules.

What FDA regulatory pathway applies to an excipient-enhanced generic?

A conventional immediate-release tablet that matches the reference product in active ingredients, strength, dosage form and route will generally pursue an ANDA. The applicant must demonstrate pharmaceutical equivalence and bioequivalence and meet FDA requirements for chemistry, manufacturing and controls.[2]

A formulation with a new dosage form, novel release profile, materially different administration method or new clinical positioning may require a 505(b)(2) pathway. That route can support differentiation but usually carries higher clinical, regulatory and development costs.

For any pathway, the critical CMC package includes:

• Excipient identity and grade.
• Supplier qualification.
• API particle-size and polymorph controls.
• Blend-uniformity data.
• Dissolution method and comparative profiles.
• Degradation and impurity controls.
• Packaging qualification.
• Process validation.
• Stability data.
• Extractables and leachables where relevant.

Are biosimilar risks relevant to Microgestin 1/20?

No. Microgestin 1/20 is a small-molecule oral tablet, not a biologic. Biosimilar approval pathways and biologic interchangeability rules do not apply. Competitive risk comes from generic ANDA products, branded generic products and alternative oral contraceptives.

Key Takeaways

• Microgestin 1/20 contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
• Its core patent and exclusivity barriers are legacy issues; generic competition is established.
• The most important formulation risk is uniform distribution of the 20 mcg ethinyl estradiol dose.
• Conventional excipients such as lactose, starch, magnesium stearate and talc provide a low-risk baseline, subject to product-specific labeling.
• Excipient substitution is commercially attractive only when it improves uniformity, dissolution, stability, manufacturability or supply resilience.
• Packaging, calendarized presentation and Microgestin Fe-style line extensions offer more practical differentiation than minor excipient changes.
• A conventional formulation should generally target the ANDA pathway. Novel dosage forms or clinical positioning may require 505(b)(2) development.
• The principal commercial threats are price erosion, supply reliability, manufacturing failures and presentation confusion.

FAQs

Can a lactose-free Microgestin 1/20 generic obtain FDA approval?

Yes, if the formulation meets applicable pharmaceutical-equivalence, bioequivalence, CMC, stability and labeling requirements. The inactive-ingredient change must be justified through the ANDA development package.

Is ferrous fumarate an active ingredient in Microgestin Fe 1/20?

No. Ferrous fumarate is included in the non-hormonal tablets. The contraceptive activity comes from norethindrone acetate and ethinyl estradiol in the active tablets.

Can a manufacturer patent a new Microgestin 1/20 excipient combination?

Potentially, but patentability depends on novelty, non-obviousness, written description, enablement and claim scope. A routine substitution of one conventional filler or lubricant for another is unlikely to provide strong protection without unexpected technical results.

Would an orally disintegrating Microgestin 1/20 product remain an ANDA?

Not necessarily. A materially different dosage form or pharmacokinetic profile may require a 505(b)(2) application rather than an ANDA.

What is the strongest commercial differentiator for a new Microgestin 1/20 supplier?

Reliable supply at competitive cost is likely to be stronger than minor excipient differentiation. Calendarized packaging, a robust low-dose manufacturing process and a complete 21-day or 28-day portfolio can improve contracting and pharmacy acceptance.

References

1. DailyMed. (n.d.). Norethindrone acetate and ethinyl estradiol tablets: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

3. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. https://www.fda.gov/drugs/generic-drugs/abbreviated-new-drug-application-anda-submissions

4. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. https://www.ich.org/

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.